[1]徐俊,戚璐,许杰,等.抗纤软肝颗粒对肝纤维化小鼠肠道黏膜通透性的影响[J].西部中医药,2022,35(07):27-30.[doi:10.12174/j.issn.2096-9600.2022.07.07]
　XU Jun,QI Lu,XU Jie,et al.Influence of Anti-fibrosis Liver-softening Granules on Intestinal Mucosal Permeability in Hepatic Fibrosis Mice[J].Western Journal of Traditional Chinese Medicine,2022,35(07):27-30.[doi:10.12174/j.issn.2096-9600.2022.07.07]
点击复制

抗纤软肝颗粒对肝纤维化小鼠肠道黏膜通透性的影响
分享到：

《西部中医药》[ISSN:2096-9600/CN:62-1204/R]

卷:
35
期数:
2022年07期
页码:
27-30
栏目:
出版日期:
2022-07-15

文章信息/Info

Title:
Influence of Anti-fibrosis Liver-softening Granules on Intestinal Mucosal Permeability in Hepatic Fibrosis Mice
作者:
徐俊, 戚璐, 许杰, 李硕, 程良斌
湖北中医药大学，湖北 武汉 430061
Author(s):
XU Jun, QI Lu, XU Jie, LI Shuo, CHENG Liangbin
Hubei University of Chinese Medicine, Wuhan 430061, China
关键词:
肝纤维化; 肠道; 紧密连接蛋白; 抗纤软肝颗粒; 小鼠
Keywords:
liver fibrosis; intestine; tight junction protein; anti-fibrosis liver-softening granules; mice
分类号:
R285.5
DOI:
10.12174/j.issn.2096-9600.2022.07.07
文献标志码:
A
摘要:
目的观察抗纤软肝颗粒对CCl4诱导肝纤维化小鼠肠道黏膜通透性的影响。 方法将35只C57BL/6雄性小鼠随机分为正常组10只，造模组25只，造模组采用CCl4皮下注射诱导肝纤维化小鼠模型，经病理学验证筛选出成功肝纤维化模型小鼠20只，将20只造模成功小鼠随机分为模型组和抗纤软肝颗粒治疗组（简称治疗组）各10只。治疗组灌胃抗纤软肝颗粒［3.9 g/（kg·d）］，模型组灌胃等体积生理盐水，干预8周后对小鼠肝组织进行HE和Masson染色，免疫组化法检测结肠组织Occludin、Claudin-1、ZO-1蛋白表达，实时荧光定量PCR（RT-qPCR）法检测结肠Occludin、Claudin-1、ZO-1 mRNA表达。 结果HE染色和Masson染色显示模型组小鼠肝组织中胶原纤维广泛增生，纤维间隔相互连接，假小叶形成，治疗组小鼠肝脏组织纤维化程度较模型组减轻；小鼠结肠Occludin、Claudin-1、ZO-1及其mRNA表达模型组均低于正常组（P＜0.05），治疗组较模型组上调（P＜0.05）。 结论抗纤软肝颗粒抗肝纤维化作用可能与其上调结肠组织中Occludin、Claudin-1、ZO-1蛋白及其基因表达水平相关。
Abstract:
ObjectiveTo observe the effects of anti-fibrosis liver-softening granules on intestinal mucosal permeability in mice suffering CCl4-induced hepatic fibrosis. MethodsA total of 35 C57BL/6 mice were randomized into ten mice in the normal group and 25 ones in the modeling group, the modeling group were prepared into hepatic fibrosis mice models by hypodermic injection of CCl4, 20 successful mice models with hepatic fibrosis were screened out via pathological verification, randomized into the model group and the treatment group of anti-fibrosis liver-softening granules (abbreviated as the treatment group), with ten mice in each group. The treatment group was drenched with anti-fibrosis liver-softening granules [3.9 g/(kg·d)], and the model group with the same volume of normal saline, after eight weeks of intervention, liver tissues were stained by HE and Masson, immunohistochemical method was applied to detect the expressions of Occludin, Claudin-1 and ZO-1 protein in colon tissue, RT-qPCR method was used to measure the expressions of Occludin, Claudin-1 and ZO-1 mRNA. ResultsHE and Masson staining displayed that collagen fibers were extensively proliferated in liver tissue of the mice in the model group, fibrous septa are interconnected, and pseudolobule were formed. The degrees of fibrosis in liver tissue of the mice in the treatment group were relieved compared with these of the model group; the expressions of Occludin, Claudin-1 and ZO-1 and their mRNA in colon of the mice in the model group were lower than these of the normal group (P<0.05), the treatment group was up-regulated compared with the model group (P<0.05). ConclusionAnti liver fibrosis effects of anti-fibrosis liver-softening granules might be related to its up-regulation of the expressions of Occludin, Claudin-1 and ZO-1 protein and mRNA in colon tissue.

相似文献/References:

[1]刘成,杨宗国,陆云飞,等.消黄方对大鼠胆汁淤积性肝纤维化的干预作用*[J].西部中医药,2012,25(11):14.
　LIU Cheng,YANG Zong-guo,LU Yun-fei,et al.Therapeutic Effects of XiaoHuangFang on Cholestatic Liver Fibrosis in Rats[J].Western Journal of Traditional Chinese Medicine,2012,25(07):14.
[2]于立友,汪龙德△,张晶,等.化纤保肝方治疗气滞血瘀型肝纤维化的临床研究*[J].西部中医药,2013,26(10):84.
　YU Liyou,WANG Longde,ZHANG Jing,et al.Clinical Study on HuaQian BaoGan Prescription in the Treatment for Hepatic Fibrosis of Qi Staganation and Blood Stasis Pattern[J].Western Journal of Traditional Chinese Medicine,2013,26(07):84.
[3]郭守强.苦参碱对肝纤维化大鼠转化生长因子β1表达的影响[J].西部中医药,2014,27(06):13.
　GUO Shouqiang.The Effects of Matrine on the Expressions of TGF-β1 of the Rats with Liver Fibrosis[J].Western Journal of Traditional Chinese Medicine,2014,27(07):13.
[4]闫雪华.恩替卡韦联合复方鳖甲软肝片治疗代偿期乙肝肝硬化疗效观察[J].西部中医药,2014,27(07):84.
　YAN Xuehua.Clinical Observation on Entecavir Combined with Compound BieJia RuanGan Tablets in Treating Decompensated Liver Cirrhosis of Hepatitis B[J].Western Journal of Traditional Chinese Medicine,2014,27(07):84.
[5]高维嘉.肠道在非酒精性脂肪肝病中医药治疗中的地位和作用[J].西部中医药,2015,28(01):137.
[6]郑燕芳.针刺配合艾灸治疗多发性硬化神经源性尿便障碍23例[J].西部中医药,2015,28(10):111.
[7]陈耀章,李根旺.冬虫夏草对心肝肾的保护作用研究[J].西部中医药,2016,29(04):127.
　CHEN Yaozhang,LI Genwang.Study on the Protective Effects of DongChong XiaCao to Heart, Liver and Kidney[J].Western Journal of Traditional Chinese Medicine,2016,29(07):127.
[8]张玉玲,闫雪华△,谢青.中药联合抗病毒药物治疗HBV所致肝纤维化的研究进展[J].西部中医药,2019,32(06):149.
　ZHANG Yuling,YAN Xuehua,XIE Qing.The Progress of Herbs Joined with Antiviral Drugs in the Treatment for HBV - induced Hepatic Fibrosis[J].Western Journal of Traditional Chinese Medicine,2019,32(07):149.
[9]段桂姣,王振常,吴珊珊.柔肝化纤颗粒对肝纤维化模型大鼠肝组织超氧化物歧化酶和丙二醛的影响[J].西部中医药,2022,35(04):30.[doi:10.12174/j.issn.2096-9600.2022.04.08]
　DUAN Guijiao,WANG Zhenchang,Wu Shanshan.Effects of Rougan Huaxian Granules on SOD and MDA in Liver Tissue of Rats with Hepatic Fibrosis[J].Western Journal of Traditional Chinese Medicine,2022,35(07):30.[doi:10.12174/j.issn.2096-9600.2022.04.08]
[10]李莎,焦战,陈青,等.瞬时弹性成像技术评价自拟中药治疗肝纤维化的临床疗效[J].西部中医药,2020,33(08):89.[doi:10.12174/j.issn.1004-6852.2020.08.23]
　LI Sha,JIAO Zhan,CHEN Qing,et al.Clinical Effects of Selfmade Herbs in Treating Liver Fibrosis Evaluated by Transient Elastography[J].Western Journal of Traditional Chinese Medicine,2020,33(07):89.[doi:10.12174/j.issn.1004-6852.2020.08.23]

备注/Memo

备注/Memo:
徐俊（1990—），男，博士学位，主治医师，讲师。研究方向：肝病的中医药防治。国家中医药管理局国家中医临床研究基地业务建设科研专项（JDZX2015179）。
更新日期/Last Update: 2022-07-15